Literature DB >> 7578114

How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium.

D J Abraham1, M K Safo, T Boyiri, R E Danso-Danquah, J Kister, C Poyart.   

Abstract

Monoaldehyde allosteric effectors of hemoglobin were designed, using molecular modeling software (GRID), to form a Schiff base adduct with the Val 1 alpha N-terminal nitrogens and interact via a salt bridge with Arg 141 alpha of the opposite subunit. The designed molecules were synthesized if not available. It was envisioned that the molecules, which are aldehyde acids, would produce a high-affinity hemoglobin with potential interest as antisickling agents similar to other aldehyde acids reported earlier. X-ray crystallographic analysis indicated that the aldehyde acids did bind as modeled de novo in symmetry-related pairs to the alpha subunit N-terminal nitrogens. However, oxygen equilibrium curves run on solutions obtained from T- (tense) state hemoglobin crystals of reacted effector molecules produced low-affinity hemoglobins. The shift in the allosteric equilibrium was opposite to that expected. We conclude that the observed shift in allosteric equilibrium was due to the acid group on the monoaldehyde aromatic ring that forms a salt bridge with the guanidinium ion of Arg 141 alpha on the opposite subunit. This added constraint to the T-state structure that ties two subunits across the molecular symmetry axis shifts the equilibrium further toward the T-state. We tested this idea by comparing aldehydes that form Schiff base interactions with the same Val 1 alpha residues but do not interact across the dimer subunit symmetry axis (a new one in this study with no acid group and others that have had determined crystal structures). The latter aldehydes shift the allosteric equilibrium toward the R-state. A hypothesis to predict the direction in shift of the allosteric equilibrium is made and indicates that it is not exclusively where the molecule binds but how it interacts with the protein to stabilize or destabilize the T- (tense) allosteric state.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578114     DOI: 10.1021/bi00046a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

2.  Distinguishing the interactions in the fructose 1,6-bisphosphate binding site of human liver pyruvate kinase that contribute to allostery.

Authors:  Arjun Ishwar; Qingling Tang; Aron W Fenton
Journal:  Biochemistry       Date:  2015-02-12       Impact factor: 3.162

3.  Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.

Authors:  Osheiza Abdulmalik; Mohini S Ghatge; Faik N Musayev; Apurvasena Parikh; Qiukan Chen; Jisheng Yang; Ijeoma Nnamani; Richmond Danso-Danquah; Dorothy N Eseonu; Toshio Asakura; Donald J Abraham; Jurgen Venitz; Martin K Safo
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-10-19

4.  Metal complexes as allosteric effectors of human hemoglobin: an NMR study of the interaction of the gadolinium(III) bis(m-boroxyphenylamide)diethylenetriaminepentaacetic acid complex with human oxygenated and deoxygenated hemoglobin.

Authors:  S Aime; G Digilio; M Fasano; S Paoletti; A Arnelli; P Ascenzi
Journal:  Biophys J       Date:  1999-05       Impact factor: 4.033

5.  Control of the allosteric equilibrium of hemoglobin by cross-linking agents.

Authors:  Michael C Marden; Marion Cabanes-Macheteau; Alexandru Babes; Laurent Kiger; Nathalie Griffon; Claude Poyart; Telih Boyiri; Martin K Safo; Donald J Abraham
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

Review 6.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

Review 7.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

8.  Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.

Authors:  Guoyan G Xu; Piyusha P Pagare; Mohini S Ghatge; Ronni P Safo; Aheema Gazi; Qiukan Chen; Tanya David; Alhumaidi B Alabbas; Faik N Musayev; Jürgen Venitz; Yan Zhang; Martin K Safo; Osheiza Abdulmalik
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

Review 9.  Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Authors:  Olujide O Olubiyi; Maryam O Olagunju; Birgit Strodel
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

10.  Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.

Authors:  Abdelsattar M Omar; Mona A Mahran; Mohini S Ghatge; Faida H A Bamane; Mostafa H Ahmed; Moustafa E El-Araby; Osheiza Abdulmalik; Martin K Safo
Journal:  Molecules       Date:  2016-08-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.